New hope for myeloma patients with kidney failure: targeted drug tested in dialysis patients

NCT ID NCT04398745

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a drug called belantamab mafodotin in people with multiple myeloma that has come back or stopped responding to treatment, and who also have kidney problems—from mild impairment to end-stage disease requiring dialysis. The drug is an antibody-drug conjugate that targets a protein on myeloma cells to deliver a cancer-killing agent. The goal is to see how the drug behaves in the body and whether it is safe in people with different levels of kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin
What this could lead to: If successful, this study could show that belantamab mafodotin is safe and works similarly in people with kidney problems, expanding treatment options for this group.
What could go wrong: This is a small, early-phase study focused on safety and drug levels, not on proving the drug works. Kidney impairment may affect how the drug is processed, and side effects could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease kidney failure plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

GSK Investigational Site

Athens, 10676, Greece
GSK Investigational Site

Athens, 11528, Greece
GSK Investigational Site

Busan, 49241, South Korea
GSK Investigational Site

Seoul, 06591, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.